Journal article
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents
Expert opinion on pharmacotherapy, Vol.25(6), pp.727-742
05/29/2024
DOI: 10.1080/14656566.2024.2354451
PMID: 38808634
Abstract
The introduction of targeted therapy and immunotherapy has tremendously changed the clinical outcomes and prognosis of cancer patients. Despite innovative pharmacological therapies and improved radiotherapy (RT) techniques, patients continue to suffer from side effects, of which oral mucositis (OM) is still the most impactful, especially for quality of life.
We provide an overview of current advances in cancer pharmacotherapy and RT, in relation to their potential to cause OM, and of the less explored and more recent literature reports related to the best management of OM. We have analyzed natural/antioxidant agents, probiotics, mucosal protectants and healing coadjuvants, pharmacotherapies, immunomodulatory and anticancer agents, photobiomodulation and the impact of technology.
The discovery of more precise pathophysiologic mechanisms of CT and RT-induced OM has outlined that OM has a multifactorial origin, including direct effects, oxidative damage, upregulation of immunologic factors, and effects on oral flora. A persistent upregulated immune response, associated with factors related to patients' characteristics, may contribute to more severe and long-lasting OM. The goal is strategies to conjugate individual patient, disease, and therapy-related factors to guide OM prevention or treatment. Despite further high-quality research is warranted, the issue of prevention is paramount in future strategies.
Details
- Title: Subtitle
- Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents
- Creators
- Margherita Gobbo - Ca' Foncello HospitalJamie Joy - Fred Hutch Cancer CenterHelena Guedes - Centro Hospitalar de Vila Nova de GaiaMuhamed Alì Shazib - High Point UniversityCarryn Anderson - University of IowaRagda Abdalla-Aslan - Technion – Israel Institute of TechnologyKhunthong Peechatanan - Monash HealthCarlo Lajolo - Università Cattolica del Sacro CuoreKhawaja Shehryar Nasir - Shaukat Khanum Memorial Cancer Hospital and Research CenterLuiz Alcino Gueiros - Hospital das Clínicas da Universidade Federal de PernambucoNivethitha Nagarajan - University of California, San FranciscoKimia Hafezi Motlagh - Tehran University of Medical SciencesAbhishek Kandwal - Swami Rama Himalayan UniversityCosimo Rupe - Università Cattolica del Sacro CuoreYuanming Xu - Tufts UniversityEli D Ehrenpreis - Advocate Lutheran General HospitalArghavan Tonkaboni - University of TehranJoel B Epstein - City Of Hope National Medical CenterPaolo Bossi - IRCCS Humanitas Research HospitalHannah R Wardill - University of AdelaideStephanie L Graff - Lifespan
- Resource Type
- Journal article
- Publication Details
- Expert opinion on pharmacotherapy, Vol.25(6), pp.727-742
- DOI
- 10.1080/14656566.2024.2354451
- PMID
- 38808634
- eISSN
- 1744-7666
- Language
- English
- Date published
- 05/29/2024
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984633060302771
Metrics
11 Record Views